Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences Ltd is a London-based biotechnology company incorporated in 1998 and listed on NASDAQ under the ticker TLSA as common stock. The company focuses on developing therapies for neurodegenerative and lung diseases, with a research pipeline centered on immunology and inflammatory conditions. Its lead candidate, Foralumab (TZLS-401), is a human anti-CD3 monoclonal antibody being studied across a range of indications, including Crohn’s disease, graft-versus-host disease, ulcerative colitis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Tiziana is also advancing TZLS-501, a fully human monoclonal antibody that targets the IL-6 receptor for potential use in inflammatory and oncology indications.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TLSA
|
$0.79
|
-19.7% Downside
|
Overvalued
|
$9.14
|
832.3% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 24, 2026
|
-6.9x
|
2,436.9x
|
—
|
131.2 M
|
120.7 M
|
0.3%
|
53.0%
|
-56.9
|
—
|
69.8%
|
